Literature DB >> 29324538

Specific Regions, Rather than the Entire Peritoneal Carcinosis Index, are Predictive of Complete Resection and Survival in Advanced Epithelial Ovarian Cancer.

Mikkel Rosendahl, Philipp Harter, Signe Frahm Bjørn, Claus Høgdall.   

Abstract

BACKGROUND: Advanced epithelial ovarian cancer (EOC) often involves the peritoneum. Because complete resection of tumor and carcinosis is the most important prognostic factor, the peritoneal carcinosis index (PCI) has been evaluated in EOC. We hypothesize that specific PCI regions comprising the small intestine with mesentery (regions 9-12) and the hepatoduodenal ligament (region 2) are more predictive of complete resection (R = 0) and survival than the entire PCI.
MATERIALS AND METHODS: We analyzed prospectively collected nationwide data from 507 patients with International Federation of Gynecology and Obstetrics stage IIIB to IVB EOC who underwent primary surgery with complete cytoreductive intent. The PCI as a predictor of incomplete resection (R > 0) was evaluated with logistic regression and receiver operating caracteristic curves. Survival analysis was performed with Kaplan-Meier curves and Cox regression.
RESULTS: Median (range) PCI was 10 (0-33) in R = 0 patients and 24 (1-39) in R > 0 patients; P < 0.0001. The PCI of regions 9 to 12 (odds ratio [OR]:1.38 (1.29-1.47; 95% confidence interval [CI]) and 2 + 9 to 12 (OR: 1.31 [1.24-1.38; 95% CI]) were more predictive of residual tumor than the entire PCI (OR: 1.10 [1.08-1.12; 95% CI]). Similarly, in receiver operating characteristic curve analyses of R greater than 0 versus R = 0, the area under the curve was higher in regions 9 to 12 (78%) and regions 2 + 9 to 12 (79%) than for the total PCI (75%).Median overall survival was 56.8 months (48.3-65.4; 95% CI) after R = 0 and 26.7 months (21.4-32.0; 95% CI) after R greater than 0 (P < 0.0001). Overall survival was 53.8 months for patients with PCI less than median (14) versus 25.7 in patients with PCI greater than median.The PCI in regions 9 to 12 (hazard ratio [HR]: 1.10 [1.07-1.13; 95% CI]) and 2 + 9 to 12 (HR: 1.08 [1.06-1.11; 95% CI]) was associated with a poorer prognosis than the entire PCI (HR: 1.03 [1.02-1.04; 95% CI]).
CONCLUSIONS: Selected PCI regions corresponding to the small intestine and hepatoduodenal ligament are more predictive of complete resection and survival than the entire PCI. This confirms that in the majority of the cases, an early intraoperative examination of those selected PCI regions - and not the entire PCI - will reveal whether R = 0 is achievable.

Entities:  

Mesh:

Year:  2018        PMID: 29324538     DOI: 10.1097/IGC.0000000000001173

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  9 in total

1.  Concordance of laparoscopic and laparotomic peritoneal cancer index using a two-step surgical protocol to select patients for cytoreductive surgery in advanced ovarian cancer.

Authors:  Martina Aida Angeles; Federico Migliorelli; Mathilde Del; Carlos Martínez-Gómez; Manon Daix; Sarah Bétrian; Erwan Gabiache; Gisèle Balagué; Sophie Leclerc; Eliane Mery; Laurence Gladieff; Gwénaël Ferron; Alejandra Martinez
Journal:  Arch Gynecol Obstet       Date:  2021-01-03       Impact factor: 2.344

Review 2.  The role of CT, PET-CT, and MRI in ovarian cancer.

Authors:  Maurits Peter Engbersen; Willemien Van Driel; Doenja Lambregts; Max Lahaye
Journal:  Br J Radiol       Date:  2021-09-01       Impact factor: 3.629

3.  The Peritoneal Cancer Index is a Strong Predictor of Incomplete Cytoreductive Surgery in Ovarian Cancer.

Authors:  Björg Jónsdóttir; Marta Lomnytska; Inger Sundström Poromaa; Ilvars Silins; Karin Stålberg
Journal:  Ann Surg Oncol       Date:  2020-05-29       Impact factor: 5.344

4.  Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis from Epithelial Ovarian Cancer: A 20-Year Single-Center Experience.

Authors:  Fabio Carboni; Orietta Federici; Isabella Sperduti; Settimio Zazza; Domenico Sergi; Francesco Corona; Mario Valle
Journal:  Cancers (Basel)       Date:  2021-01-29       Impact factor: 6.639

5.  The role of computed tomography in the assessment of tumour extent and the risk of residual disease after upfront surgery in advanced ovarian cancer (AOC).

Authors:  Mihaela Asp; Susanne Malander; Nils-Olof Wallengren; Sonja Pudaric; Johan Bengtsson; Hanna Sartor; Päivi Kannisto
Journal:  Arch Gynecol Obstet       Date:  2022-03-02       Impact factor: 2.493

6.  Correlation of surgeon radiology assessment with laparoscopic disease site scoring in patients with advanced ovarian cancer.

Authors:  Nicole D Fleming; Shannon N Westin; Larissa A Meyer; Aaron Shafer; Jose Alejandro Rauh-Hain; Michaela Onstad; Lauren Cobb; Michael Bevers; Bryan M Fellman; Jennifer Burzawa; Priya Bhosale; Behrouz Zand; Amir Jazaeri; Charles Levenback; Robert L Coleman; Pamela T Soliman; Anil K Sood
Journal:  Int J Gynecol Cancer       Date:  2020-11-05       Impact factor: 3.437

7.  Small Bowel PCI Score as a Prognostic Factor of Ovarian Cancer Patients Undergoing Cytoreductive Surgery (CRS) with Hyperthermic Intraperitoneal Chemotherapy (HIPEC), a Retrospective Analysis of 130 Patients.

Authors:  Christos Iavazzo; Alexandros Fotiou; Victoria Psomiadou; Sofia Lekka; Dimitrios Katsanos; John Spiliotis
Journal:  Indian J Surg Oncol       Date:  2021-03-03

8.  Patients with stage IV epithelial ovarian cancer: understanding the determinants of survival.

Authors:  Yohann Dabi; Cyrille Huchon; Lobna Ouldamer; Sofiane Bendifallah; Pierre Collinet; Alexandre Bricou; Emile Daraï; Marcos Ballester; Vincent Lavoue; Bassam Haddad; Cyril Touboul
Journal:  J Transl Med       Date:  2020-03-23       Impact factor: 5.531

9.  Adherence to French and ESGO Quality Indicators in Ovarian Cancer Surgery: An Ad-Hoc Analysis from the Prospective Multicentric CURSOC Study.

Authors:  Martinez Alejandra; Witold Gertych; Christophe Pomel; Gwenael Ferron; Amelie Lusque; Martina Aida Angeles; Eric Lambaudie; Roman Rouzier; Naoual Bakrin; Francois Golfier; Olivier Glehen; Michel Canis; Nicolas Bourdel; Nicolas Pouget; Pierre-Emmanuel Colombo; Frédéric Guyon; Jacques Meurette; Denis Querleu
Journal:  Cancers (Basel)       Date:  2021-03-30       Impact factor: 6.639

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.